Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab/tremelimumab plus paclitaxel in hypermutated gastric cancer after failure of first-line chemotherapy
KCT0004533Phase 2Completed
- Sponsor
- Samyang Biopharmaceuticals Corporation
- Start
- Sep 2017
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, single-arm trial of durvalumab, tremelimumab and paclitaxel in gastric cancer (GC), sponsored by Samyang Biopharmaceuticals Corporation. Started Sep 2017; status: completed.
02
Drugs
durvalumabtremelimumabpaclitaxel
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on KCT0004533.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0004533.